Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.110
+0.150 (5.07%)
At close: May 21, 2026, 4:00 PM EDT
3.100
-0.010 (-0.32%)
Pre-market: May 22, 2026, 7:55 AM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Recursion Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $6.64. The average 1-year stock price forecast is 113.50% higher than the current stock price, while the lowest is $3.00 (-3.54%) and the highest is $10 (+221.54%).
Price Target: $6.64 (+113.50%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 1 | 1 | 2 | 2 |
| Hold | 2 | 2 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $5.5 | Hold | Maintains | $5 → $5.5 | +76.85% | May 14, 2026 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +157.23% | May 7, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +221.54% | Apr 30, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +92.93% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +157.23% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
68.54M
from 74.68M
Decreased by -8.22%
Revenue Next Year
116.96M
from 68.54M
Increased by 70.64%
EPS This Year
-0.95
from -1.44
EPS Next Year
-0.85
from -0.95
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 96.6M | 336.0M | |
| Avg | 68.5M | 117.0M | |
| Low | 41.6M | 20.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 29.4% | 390.2% | |
| Avg | -8.2% | 70.6% | |
| Low | -44.3% | -70.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.95 | -0.46 | |
| Avg | -0.95 | -0.85 | |
| Low | -0.98 | -0.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.